Prospects and applications of nanobiotechnology: A medical perspective

Journal of Nanobiotechnology

Volumn 10, Issue , 2012, Pages

  Fakruddin, Md ^a   Hossain, Zakir ^a   Afroz, Hafsa ^b  

^a Bangladesh Council of Scientific and Industrial Research   (Bangladesh)

^b PRIMEASIA UNIVERSITY   (Bangladesh)

Author keywords

Applications; Medical; Nanobiotechnology; Prospects

Indexed keywords

BIOLOGICAL FIELDS; CLINICAL APPLICATION; CLINICAL TRIAL; DEGREE OF SPECIFICITY; HUMAN HEALTH; MEDICAL; MEDICAL SCIENCE; MORAL CONCERNS; NANO-DEVICES; PROSPECTS; SIDE EFFECT; SUB-CELLULAR; THERAPEUTIC EFFICACY;

APPLICATIONS; HEALTH CARE; MEDICINE; NANOBIOTECHNOLOGY; TISSUE;

MEDICAL NANOTECHNOLOGY;

ANTIGEN; ANTINEOPLASTIC AGENT; BIOMATERIAL; CALCIUM; CARDIAC AGENT; COMPLEMENTARY DNA; INSULIN; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NANOMATERIAL; NANOPARTICLE; NANOSPHERE; PLASMID DNA; POLYMER; QUANTUM DOT; VIRUS VECTOR;

BIOTECHNOLOGY; BLOOD BRAIN BARRIER; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELL SPECIFICITY; CHROMATOPHORE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DENTAL PROCEDURE; DIAGNOSTIC PROCEDURE; DIP PEN NANOLITHOGRAPHY; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC ENGINEERING AND GENE TECHNOLOGY; HAZARD RATIO; HEALTH; HEALTH CARE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMPLANT; LIPID BILAYER; LIPOSOMAL DELIVERY; MEDICAL PRACTICE; MEDICINE; NANOBIOTECHNOLOGY; NANODEVICE; NANOFABRICATION; NANOROBOTIC; NANOTECHNOLOGY; NONHUMAN; ORTHOPEDICS; PARTICLE SIZE; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROTEIN MICROARRAY; REVIEW; ROBOTICS; TARGET CELL; TISSUE SPECIFICITY; TOTAL QUALITY MANAGEMENT; VACCINATION;

BIOMEDICAL TECHNOLOGY; BIOTECHNOLOGY; HUMANS; NANOTECHNOLOGY;

EID: 84865287325     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-10-31     Document Type: Review

References (58)

1. Emerich DF, Thanos CG. Nanotechnology and medicine. Expert Opin Biol Ther 2003, 3:655-663. 10.1517/14712598.3.4.655, 12831370.
2. Sahoo KS, Labhasetwar V. Nanotech approaches to drug delivery and imaging. DDT 2003, 8(24):1112-1120.
3. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005, 4:363-374.
4. Vasir JK, Reddy MK, Labhasetwar V. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005, 1:47-64.
5. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284. 10.1016/S0168-3659(99)00248-5, 10699287.
6. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
7. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822. 10.1126/science.1095833, 15031496.
8. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998, 15:67-74. 10.3109/02652049809006836, 9463808.
9. Garcia-Garcia E, Gil S, Andrieux K, Desmaële D, Nicolas V, Taran F, Georgin D, Andreux JP, Roux F, Couvreur P. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol Life Sci 2005, 62(12):1400-1408. 10.1007/s00018-005-5094-3, 2773840, 15905957.
10. Feng SS, Mu L, Win KY, et al. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004, 11:413-424. 10.2174/0929867043455909, 14965222.
11. de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004, 34:3702-3712. 10.1002/eji.200425022, 15517615.
12. Shaffer C. Nanomedicine transforms drug delivery. Drug Discov Today 2005, 10:1581-1582.
13. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005, 19:311-330. 10.1096/fj.04-2747rev, 15746175.
14. Drexler EK. Nanosytems: Molecular Machinery, Manufacturing and Computation 1992, John Wiley & Sons, New York.
15. Nanosphere Inc 2004, Available at http://www.nanosphere-inc.com, Nanosphere Inc.
16. Lee KB, Park SJ, Mirkin C, Smith J, MrKisch MA. Protein Nanoarrays generated by Dip-Pen Nanolithography. Science 2002, 295:1702-1705. 10.1126/science.1067172, 11834780.
17. NanoInk Inc 2004, Available at http://www.nanoink.net, NanoInk Inc.
18. NBTC (Nano-biotechnology Center, Cornell University) 2004, Available at http://www.nbtc.cornell.edu/default.htm, NBTC (Nano-biotechnology Center, Cornell University).
19. Lin H, Datar RH. Medical applications of nanotechnology. Natl Med J India 2006, 19:27-32.
20. Guccione S, Li KC, Bednarski MD. Vascular-targeted nanoparticles for molecular imaging and therapy. Methods Enzymol 2004, 386:219-236.
21. LaVan DA, Lynn DM, Langer R. Timeline: Moving Smaller in drug discovery and delivery. Nat Rev Drug Discov 2002, 1:77-84. 10.1038/nrd707, 12119612.
22. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 2002, 249:101-118. 10.1016/S0378-5173(02)00461-1, 12433438.
23. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004, 56:1527-1535.
24. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res 2001, 18:1521-1527. 10.1023/A:1013018111829, 11758758.
25. Arbos P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Release 2004, 96:55-65. 10.1016/j.jconrel.2004.01.006, 15063029.
26. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target 2003, 11:495-507. 10.1080/10611860410001670026, 15203918.
27. Koping-Hoggard M, Sanchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 2005, 4:185-196. 10.1586/14760584.4.2.185, 15889992.
28. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly (d, l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002, 19:1480-1487. 10.1023/A:1020452531828, 12425465.
29. Yotsuyanagi T, Hazemoto N. Cationic liposomes in gene delivery. Nippon Rinsho 1998, 56:705-712.
30. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006, 208:299-318. 10.1002/path.1896, 16362990.
31. Davis SS. Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 1997, 15:217-224. 10.1016/S0167-7799(97)01036-6, 9183864.
32. Hart SL. Lipid carriers for gene therapy. Curr Drug Deliv 2005, 2:423-428. 10.2174/156720105774370230, 16305445.
33. Ewert K, Evans HM, Ahmad A, Slack NL, Lin AJ, Martin-Herranz A, et al. Lipoplex structures and their distinct cellular pathways. Adv Genet 2005, 53:119-155.
34. Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM, et al. Organ specific gene expression in the rhesus monkey eye following intravenous nonviral gene transfer. Mol Vis 2003, 9:465-472.
35. Elan Corporation, PLC 2004, Available at http://www.elan.com, Elan Corporation, PLC.
36. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2006, 26:435-441.
37. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347. 10.1016/S0169-409X(02)00228-4, 12628320.
38. West JL, Halas NJ. Applications of nanotechnology to biotechnology commentary. Curr Opin Biotechnol 2000, 11:215-217. 10.1016/S0958-1669(00)00082-3, 10753774.
39. Shi H, Tsai WB, Garrison MD, Ferrari S, Ratner BD. Templateimprinted nanostructured surfaces for protein recognition. Nature 1999, 398:593-597. 10.1038/19267, 10217142.
40. Sims MR. Brackets, epitopes and flash memory cards: a futuristic view of clinical orthodontics. Aust Orthod J 1999, 15:260-268.
41. Slavkin HC. Entering the era of molecular dentistry. J Am Dent Assoc 1999, 130:413-417.
42. Ure D, Harris J. Nanotechnology in dentistry: reduction to practice. Dent Update 2003, 30:10-15.
43. Fartash B, Tangerud T, Silness J, Arvidson K. Rehabilitation of mandibular edentulism by single crystal sapphire implants and overdentures: 3-12 year results in 86 patients. A dual center international study. Clin Oral Implants Res 1996, 7:220-229. 10.1034/j.1600-0501.1996.070304.x, 9151586.
44. Shellhart WC, Oesterle LJ. Uprighting molars without extrusion. J Am Dent Assoc 1999, 130:381-385.
45. Webster TJ, Waid MC, McKenzie JL, Price RL, Ejiofor JU. Nanobiotechnology: carbon nanofibres as improved neural and orthopedic implants. Nanotechnology 2004, 15:48-54.
46. Price RL, Waid MC, Haberstroh KM, Webster TJ. Selective bone cell adhesion on formulations containing carbon nanofibers. Biomaterials 2003, 24:1877-1887. 10.1016/S0142-9612(02)00609-9, 12615478.
47. Buzea C, Pacheco I, Robbie K. Nanomaterials and nanoparticles: Sources and Toxicity. Biointerphases 2007, 2:MR17. 10.1116/1.2815690, 20419892.
48. Milunovich S, Roy J. The next small thing: An Introduction to nanotechnology. Merrill Lynch Report, September 4, 2001
49. Hamad-Schifferli K, Schwartz J, Santos AT, Zhang S, Jacobson J. Remote electronic control of DNA hybridization through inductive coupling to an attached metal nanocrystal antenna. Nature 2002, 415:152-155. 10.1038/415152a, 11805829.
50. Li Z, Hulderman T, Salmen R, Chapman R, Leonard SS, Young SH, et al. Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ Health Perspect 2007, 115:377-382. 1849906, 17431486.
51. Nijhara R, Balakrishnan K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine 2006, 2:127-136. 10.1016/j.nano.2006.04.005, 17292125.
52. Lam CW, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 2004, 77:126-134.
53. Williams D. The risks of nanotechnology. Med Device Technol 2004, 15:9-10.
54. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 2004, 112:1058-1062. 10.1289/ehp.7021, 1247377, 15238277.
55. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006, 114:1172-1178. 10.1289/ehp.9030, 1552007, 16882521.
56. Radomski A, Jurasz P, Onso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005, 146:882-893. 10.1038/sj.bjp.0706386, 1751219, 16158070.
57. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles : pharmacological and toxicological significance. Br J Pharmacol 2007, 150:552-558. 2189773, 17245366.
58. Chen Z, Meng H, Xing G, Chen C, Zhao Y, Jia G, et al. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett 2006, 163:109-120. 10.1016/j.toxlet.2005.10.003, 16289865.